Evidence map›Paper›PMID 23902763›Full record

ArticleThe Journal of biological chemistry2013

Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.

JiHoon Kang, EunGi Kim, Wanyeon Kim, Ki Moon Seong, HyeSook Youn, Jung Woo Kim, Joon Kim, BuHyun Youn

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Protective Effects of Rhamnetin in Carbapenem-ResistantInternational journal of molecular sciences · 2023
    Article
  18. Review
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

JiHoon KangDepartment of Biological Sciences, Pusan National University, Busan 609-735.
EunGi KimDepartment of Biological Sciences, Pusan National University, Busan 609-735.
Wanyeon KimDepartment of Biological Sciences, Pusan National University, Busan 609-735.
Ki Moon SeongDivision of Radiation Effect Research, Radiation Health Research Institute, Korea Hydro and Nuclear Power Co., Ltd., Seoul 132-703.
HyeSook YounDepartment of Bioscience and Biotechnology/Institute of Bioscience, Sejong University, Seoul 143-747.
Jung Woo KimDepartment of Life Science and Biotechnology, Pai Chai University, Daejeon 302-735.
Joon KimSchool of Life Sciences and Biotechnology and BioInstitute, Korea University, Seoul 136-701, South Korea.
BuHyun YounDepartment of Biological Sciences, Pusan National University, Busan 609-735. Electronic address: bhyoun72@pusan.ac.kr.
Pusan National University · KRPai Chai University · KRBiotechnology Institute · USKorea Atomic Energy Research Institute · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioresistance is a major cause of decreasing the efficiency of radiotherapy for non-small cell lung cancer (NSCLC). To understand the radioresistance mechanisms in NSCLC, we focused on the radiation-induced Notch-1 signaling pathway involved in critical cell fate decisions by modulating cell proliferation. In this study, we investigated the use of Notch-1-regulating flavonoid compounds as novel therapeutic drugs to regulate radiosensitivity in NSCLC cells, NCI-H1299 and NCI-H460, with different levels of radioresistance. Rhamnetin and cirsiliol were selected as candidate Notch-1-regulating radiosensitizers based on the results of assay screening for activity and pharmacological properties. Treatment with rhamnetin or cirsiliol reduced the proliferation of NSCLC cells through the suppression of radiation-induced Notch-1 expression. Indeed, rhamnetin and cirsiliol increased the expression of tumor-suppressive microRNA, miR-34a, in a p53-dependent manner, leading to inhibition of Notch-1 expression. Consequently, reduced Notch-1 expression promoted apoptosis through significant down-regulation of the nuclear factor-κB pathway, resulting in a radiosensitizing effect on NSCLC cells. Irradiation-induced epithelial-mesenchymal transition was also notably attenuated in the presence of rhamnetin and cirsiliol. Moreover, an in vivo xenograft mouse model confirmed the radiosensitizing and epithelial-mesenchymal transition inhibition effects of rhamnetin and cirsiliol we observed in vitro. In these mice, tumor volume was significantly reduced by combinational treatment with irradiation and rhamnetin or cirsiliol compared with irradiation alone. Taken together, our findings provided evidence that rhamnetin and cirsiliol can act as promising radiosensitizers that enhance the radiotherapeutic efficacy by inhibiting radiation-induced Notch-1 signaling associated with radioresistance possibly via miR-34a-mediated pathways.

Indexed as

Epithelial-Mesenchymal TransitionGamma RaysGene Expression Regulation, NeoplasticAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationFlavonesHumansLung NeoplasmsMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsNF-kappa BcirsiliolFlavonesMicroRNAsMIRN34 microRNA, humanNF-kappa BNOTCH1 protein, humanQuercetinReceptor, Notch1rhamnetinRNA, NeoplasmTP53 protein, humanTumor Suppressor Protein p53Cancer TherapyCirsiliolEMTLung CancermiR-34aNatural ProductsNotch-1Radiation BiologyRadiosensitizationRhamnetin

Identifiers

PMID23902763
PMCPMC3779729
OpenAlexW1987275335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.